Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Hepatitis C
Intervention: Boceprevir (Drug); Peginterferon Alfa-2b 1.5 mcg/kg/week (Drug); Ribavirin (Drug)
Phase: Phase 3
Status: Withdrawn
Sponsored by: Merck Sharp & Dohme Corp.
Summary
This study is designed to assess the safety and tolerability of boceprevir dosed 800 mg
three times daily (TID) orally (PO) in combination with Peginterferon alfa-2b (PEG2b) 1. 5
mcg/kg once a week (QW) administered subcutaneously (SC) plus ribavirin (RBV) (800 to 1400
mg/day) PO in Response Guided Therapy (RGT) in adult Vietnamese subjects with Chronic
Hepatitis C, Genotype 1 (CHC GT1) who failed prior treatment with any interferon and
ribavirin in Vietnam.
Clinical Details
Official title: An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus Ribavirin in Vietnam
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Percentage of Participants Achieving Sustained Virologic Response (SVR)Percentage of Participants Experiencing a Serious Adverse Event (SAE) During the Study Therapy Period
Detailed description:
Each participant will participate in the trial for a maximum of 80 weeks from the time the
participant signs the Informed Consent Form (ICF) through the final contact. After a
Screening phase of approximately 4 to 8 weeks, each participant will receive treatment for
approximately 36-48 weeks depending on response at Treatment Week 8.
A 4-week lead-in period with PEG2b plus RBV will be followed by 32 weeks boceprevir plus
PEG2b/RBV. At treatment Week 36 participants will be assigned to the following treatments
depending on the virologic response at Week 8 and cirrhotic status:
1. For non-cirrhotic participants with undetectable hepatitis C virus (HCV)-RNA on Week 8,
all treatment will be discontinued at Week 36.
2. For non-cirrhotic participants with detectable HCV-RNA on Week 8, only boceprevir
treatment will be discontinued at Week 36 and PEG2b and RBV treatment will continue to
Week 48.
3. For cirrhotic participants, the boceprevir plus PEG2b/RBV treatment will continue to
Week 48.
The study has a futility rule at Week 12 at which point all subjects with detectable HCV-RNA
levels will be discontinued. All participants will have a post-treatment follow-up period of
at least 24 weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Weight ≥ 40 kg to ≤ 125 kg
- Sexually active male participants and female participants of child-bearing potential
must agree to use a medically acceptable form of contraception
- Must have documented Chronic Hepatitis C Genotype 1 infection
- Must have failed prior treatment with interferon plus ribavirin
- Must have completed treatment with interferon plus ribavirin for at least 12 weeks
- Must have had a liver biopsy or Fibroscan to determine status as cirrhotic or
non-cirrhotic
- Participants with cirrhosis must have had an ultrasound or imaging study within 6
months of the Screening visit
Exclusion Criteria:
- Known co-infection with the human immunodeficiency virus (HIV) or the hepatitis B
virus
- Prior discontinuation of treatment with interferon or ribavirin due to the occurrence
of an adverse event(s) considered by the investigator to be possibly or probably
related to the treatment
- Treatment with ribavirin within 90 days and any interferon within 1 month of the
Screening visit
- Treatment with any investigational drug within 30 days prior to the Screening visit
- Treatment with midazolam, pimozide, amiodarone, flecainide, propafenone, quinidine,
or ergot derivatives within 2 weeks prior to the Day 1 visit
- Participation in any investigational trial within 30 days of the Screening visit
- Evidence of decompensated liver disease
- Child Pugh score > 6 (Class B and C)
- Diabetic and/or hypertensive participants with clinically significant ocular
examination findings
- Pre-existing psychiatric conditions
- Clinical diagnosis of substance abuse
- Active or suspected malignancy
- Pregnant or nursing
Locations and Contacts
Additional Information
Starting date: May 2014
Last updated: September 26, 2014
|